Table 4 Demographics and baseline characteristics in the 1-year observational therapeutic study
Characteristics | Risperidone (long-acting, injectable) (RLAI) group | Routine treatment group |
|---|---|---|
Number of patients | 42 | 35 |
Sex: male/female | 18/24 | 16/19 |
Age (SD) | 43.7 (13.4) | 45.4 (14.2) |
Duration of disease (SD) | 16.8 (11.7) | 15.7 (12.3) |
Number of previous hospitalizations (SD) | 4.7 (2.5) | 4.2 (2.8) |
Paranoid schizophrenia: | Â | Â |
Continuous course | 15/35.7% | 11/31.4% |
Episodic course with progressive and stable deficit | 15/35.7% | 13/37.1% |
Remittent course | 0 | 0 |
Hebephrenic schizophrenia | 0 | 0 |
Catatonic schizophrenia | 1/2.4% | 1/2.9% |
Undifferentiated schizophrenia | 3/7.1% | 2/5.7% |
Residual schizophrenia | 5/11.9% | 6/17.1% |
Simple schizophrenia | 3/7.1% | 2/5.7% |
Schizoaffective disorder | 0 | 0 |
PANSS total score (SD) | 66.1 (10.7) | 68.7 (12.3) |
PANSS positive score (items 1 to 7) (SD) | 14.5 (4.5) | 16.0 (5.1) |
PANSS negative score (items 8 to 14) (SD) | 18.8 (4.3) | 19.1 (4.8) |
PANSS general score (items 15 to 30) (SD) | 33.1 (5.4) | 35.3 (6.8) |
Simpson-Angus scale score (SD) | 4.9 (6.3) | 5.1 (6.1) |
PSP score (SD) | 52.0 (12.3) | 51.3 (13.1) |
ROMI score | Â | Â |
Compliance subscale | 14.9 (2.3) | 15.4 (2.6) |
Non-compliance subscale | 17.1 (3.3) | 16.4 (4.1) |